12 Mar
Pharmaceutical Approval Update: Lapatinib (Tykerb)
Manufacturer: GlaxoSmithKline, Research Triangle Park, NC Indication: Lapatinib is indicated in combination with capecitabine (Xeloda, Roche) for patients with advanced or metastatic breast cancer whose tumors overexpress a marker called human epidermal receptor type-2 (HER-2) and who have received prior therapy, including an anthracycline, a tax-ane, and trastuzumab (Herceptin, Genentech).